甲氨蝶呤的亚硝胺不在脂肪胺上:蝶啶环外那个弱碱氮,为什么反而最容易被亚硝化Methotrexate's Nitrosamine Is Not on an Aliphatic Amine: Why the Weakly Basic Nitrogen Outside the Pteridine Ring Is the Easiest to Nitrosate
谈亚硝胺,默认画面是「仲胺遇上亚硝酸盐」。甲氨蝶呤↗把这画面撕开一道口子:它的亚硝化位点是一个碱性极弱的芳香仲胺;检测与限度换算也是另一套逻辑。申报常卡在这些「不合常理」处。
Mention nitrosamines and the default picture is a secondary amine meeting nitrite. Methotrexate↗ tears a hole in that picture: its nitrosation site is an aromatic secondary amine of extremely low basicity, and detection and dose-to-limit conversion follow an entirely different logic. Regulatory filings routinely stall on exactly these counter-intuitive points.
Note: product names shown in red (marked with ↗) are clickable. Click to open the product page for structure, CAS number, purity and lead time.
一、结构定位:一个弱碱氮为什么会被亚硝化1. Structural positioning: why a weakly basic nitrogen gets nitrosated
关键要点Key points
- 甲氨蝶呤的可亚硝化位点不在脂肪胺上,而在The nitrosatable site in methotrexate is not an aliphatic amine but the 蝶啶环外的芳香仲胺aromatic secondary amine outside the pteridine ring——氮直接挂在缺电子杂环上,碱性极弱,却能形成稳定的 N-亚硝基产物。— the nitrogen hangs directly on an electron-poor heterocycle and is extremely weakly basic, yet it still forms a stable N-nitroso product.
- 这个亚硝胺在 EP 中编为In the EP this nitrosamine is designated 杂质 LImpurity L,目录里以「N-亚硝基甲氨蝶呤 EP 杂质 L」命名;它不是外来残留物,而是, and the catalogue lists it as "N-Nitroso Methotrexate EP Impurity L". It is not an external residue but a 药物本体相关的 NDSRIdrug-substance-related NDSRI。
- 日剂量把它推向更严的一端:常见剂量跨 2.5 mg 到 1000 mg 以上,同一 ppm 限值在不同规格下的绝对量差三个数量级,限度须按规格分档。Dosing pushes it to the stricter end: common doses span 2.5 mg to over 1000 mg, so the same ppm limit corresponds to absolute amounts three orders of magnitude apart across strengths, and limits must be tiered by strength.
- 常规方法论失灵两次:氮极弱碱使亚硝化剂不易生成;分子在紫外强吸收,痕量检测的基质效应也与小分子亚硝胺完全不同。Conventional methodology fails twice over: the extremely weak basicity makes the nitrosating agent hard to generate, and the molecule absorbs strongly in the UV, so matrix effects in trace detection differ completely from those of small-molecule nitrosamines.
甲氨蝶呤(CAS 59-05-2)分三块:2,4-二氨基蝶啶环、对氨基苯甲酰基、带两个羧基的谷氨酸。二氢叶酸还原酶抑制活性来自蝶啶环与谷氨酸的配合,而Methotrexate (CAS 59-05-2) splits into three parts: a 2,4-diaminopteridine ring, a p-aminobenzoyl group and a glutamic acid bearing two carboxyls. Dihydrofolate reductase inhibition comes from the combined action of the pteridine ring and the glutamate, and the 问题集中的地方在中段trouble concentrates in the middle segment——蝶啶环 4 位氨基与苯甲酰基之间那个氮。— the nitrogen between the 4-amino group of the pteridine and the benzoyl group.
这个氮的特殊性有三重。This nitrogen is special in three ways. 其一First,它是 It is an 芳香仲胺aromatic secondary amine,具备亚硝化的基本前提:N 上有氢且与芳环共轭。, meeting the basic precondition for nitrosation: hydrogen on the nitrogen and conjugation with an aromatic ring. 其二Second,两侧都是强吸电子体系——缺电子的蝶啶并嘧啶环与苯甲酰羰基,碱性极弱,常规 pH 下几乎不被质子化。, both flanks are strongly electron-withdrawing — the electron-poor pteridopyrimidine ring and the benzoyl carbonyl — so basicity is extremely weak and it is barely protonated at ordinary pH. 其三Third,正因为碱性弱,孤对电子不易与质子结合,反而保留了与亚硝化剂(NO⁺ 亲电体)反应的能力。, precisely because basicity is weak the lone pair does not readily bind a proton, which preserves its ability to react with the nitrosating agent (the NO⁺ electrophile).[1]
三条合起来解释了反直觉的事实:Together the three explain a counter-intuitive fact: 越难质子化的仲胺,越容易在酸性环境中被亚硝化the harder a secondary amine is to protonate, the more readily it is nitrosated in acidic media。经典机理的第一步是游离胺与 NO⁺ 结合,质子化正是竞争反应:碱性弱,被质子夺走的少,游离胺比例反而高。芳香胺与酰胺氮值得单列,根子在此。. The first step of the classical mechanism is the free amine combining with NO⁺, and protonation is the competing reaction: with weak basicity fewer molecules are taken by protons, so the free-amine fraction is actually higher. That is the root reason aromatic amines and amide nitrogens deserve separate treatment.


二、这个亚硝胺在 EP 体系里的位置2. Where this nitrosamine sits in the EP system
欧洲药典对甲氨蝶呤用字母编号,A 至 L 共 12 个。多数是经典的工艺与降解杂质:蝶啶环取代变化、侧链水解、光解产物。而 The European Pharmacopoeia letter-numbers methotrexate impurities, A through L, twelve in all. Most are classical process and degradation impurities: substituent changes on the pteridine ring, side-chain hydrolysis and photolysis products. The position of L 的位置被 N-亚硝基衍生物占据,这在 EP 各论里并不常见:多数品种的亚硝胺按「未指定杂质」或单独方法学项目处理,能拿到专属字母,说明它在本品种上确属常规可检出、需定量的对象。 is occupied by the N-nitroso derivative, which is unusual in an EP monograph: for most products nitrosamines are handled as unspecified impurities or as a separate methodological item, so earning a dedicated letter means it is genuinely routine, detectable and quantifiable for this product.[2]
本目录的甲氨蝶呤品种页共 85 张产品卡,覆盖 EP 杂质 A 至 L 与编号杂质 13 至 116 的大量条目。与亚硝胺直接相关的是那条以「N-亚硝基甲氨蝶呤 EP 杂质 L」命名的产品卡(CAS 3076947-02-6);另有同名但不同 CAS 的一个条目(52980-68-4,标注为「甲氨蝶呤杂质 12(甲氨蝶呤 EP 杂质 L)」),以及分子式为 C13H16N2O5 的三条同式条目(EP 杂质 L、杂质 95、杂质 109)。The methotrexate product page in this catalogue carries 85 product cards, covering EP Impurities A to L together with a large set of numbered impurities from 13 to 116. Directly relevant to nitrosamines is the card named "N-Nitroso Methotrexate EP Impurity L" (CAS 3076947-02-6); there is also an entry sharing the name but with a different CAS (52980-68-4, labelled "Methotrexate Impurity 12 (Methotrexate EP Impurity L)"), plus three entries with the formula C13H16N2O5 (EP Impurity L, Impurity 95 and Impurity 109).
注意:Note: 目录中以「EP 杂质 L」命名的条目不止一条,CAS 也不一致, the catalogue holds more than one entry named "EP Impurity L" and their CAS numbers do not agree。这是对照品行业的常见现象:早期按字母上架的条目后来随结构修订而分化。采购建档须以结构为锚,用分子式与谱图交叉确认。. This is common in the reference-standard trade: entries listed early by letter later diverged as structures were revised. Anchor sourcing records on structure and cross-check with formula and spectra.
上面这条 CDE 数据反映的是受理记录与申报单位数量,不代表批准状态。The CDE figures above reflect acceptance records and applicant counts, not approval status.
三、剂量决定尺度:同一 ppm 值差三个数量级3. Dose sets the scale: one ppm value, three orders of magnitude apart
亚硝胺限度的算法统一:取可接受摄入量(AI,ng/天),除以最大日剂量(g/天),乘 1000 换算成 ppm 或 μg/g。让甲氨蝶呤棘手的是分母——它是Nitrosamine limits are calculated the same way everywhere: take the acceptable intake (AI, ng/day), divide by the maximum daily dose (g/day) and multiply by 1000 to convert to ppm or μg/g. What makes methotrexate awkward is the denominator — it is a 剂量跨度极大product with an enormous dose range的品种。.
同一活性成分,肿瘤治疗按体表面积折算可达克级单次给药;自身免疫病(类风湿关节炎、银屑病)则常按每周数毫克给药。同一份原料药被做成两种剂量相差三个数量级的制剂,标准若只写一个 ppm 值,必然要么对大规格过宽、要么对小规格过严。The same active substance can be dosed at gram level per administration in oncology, scaled to body surface area, while autoimmune indications (rheumatoid arthritis, psoriasis) are often dosed in milligrams per week. One API becomes two products whose doses differ by three orders of magnitude, so a single ppm figure in the specification is bound to be too loose for the large strength or too tight for the small one.
| 剂型场景Dosage scenario | 典型剂量量级Typical dose magnitude | 限度设定的主导因素Dominant factor in limit setting | 对方法的要求Demand on the method |
|---|---|---|---|
| 肿瘤化疗(注射用)Oncology chemotherapy (injectable) | 克级,按体表面积折算gram level, scaled to body surface area | 按 AI 折算后 ppm 极低,百分比与绝对量双约束ppm after AI conversion is very low, constrained both as a percentage and as an absolute amount | 定量限须低于折算值,需 LC-MS/MSquantitation limit must sit below the converted value; LC-MS/MS required |
| 自身免疫病(口服小规格)Autoimmune disease (small oral strength) | 毫克级,每周给药milligram level, weekly dosing | AI 除以周剂量后再按周均摊,ppm 值相对宽松AI divided by weekly dose and averaged over the week, so the ppm is relatively lenient | HPLC-UV 或 LC-MS/MS 均可,但须覆盖 LHPLC-UV or LC-MS/MS both acceptable, provided L is covered |
| 外用制剂Topical preparations | 毫克级,面积相关milligram level, area dependent | 经皮吸收比例成为额外变量percutaneous absorption becomes an extra variable | 按制剂实际暴露量评估assess against actual product exposure |
表注:本表只给量级关系,不列具体限值;数值须以现行 ICH M7 与监管最新亚硝胺限度文件为准,并随品种 AI 修订更新。Table note: this table gives only order-of-magnitude relationships, not specific limits; values must follow current ICH M7 and the latest regulatory nitrosamine limit documents, and are updated as product-specific AIs are revised.
四、这个亚硝胺从哪来:三条比「胺 + 亚硝酸盐」更现实的路径4. Where the nitrosamine comes from: three more realistic routes than "amine plus nitrite"
若只在合成路线上找「仲胺 + 亚硝酸盐」,甲氨蝶呤看上去风险不高:关键中间体是 2,4-二氨基-6-溴甲基蝶啶一类的蝶啶片段与对氨基苯甲酰谷氨酸缩合,工艺通常不直接引入亚硝酸盐。实际风险有三条更现实的入口。Look for "secondary amine plus nitrite" in the synthetic route alone and methotrexate seems low risk: the key intermediates are a pteridine fragment such as 2,4-diamino-6-bromomethylpteridine condensed with p-aminobenzoylglutamic acid, and the process does not usually introduce nitrite directly. The real risk enters by three more realistic doors.
其一,工艺中的亚硝化剂污染。First, nitrosating-agent contamination in the process. 蝶啶环合成常涉及亚硝酸盐参与的重氮化或环合,残留亚硝酸根若带入下游、与分子自身的芳香仲胺相遇,亚硝化条件就齐了。这类风险的特点是同车间、跨品种——问题常在共用设备与回收溶剂,而非反应式本身。 Pteridine ring synthesis often involves diazotisation or cyclisation with nitrite, and if residual nitrite carries downstream and meets the molecule's own aromatic secondary amine, the conditions for nitrosation are complete. This risk is characteristically shared across a plant and across products — the problem usually lies in shared equipment and recovered solvents, not in the reaction scheme itself.
其二,制剂端的水分与辅料。Second, moisture and excipients at the formulation end. 口服固体制剂中,部分辅料(含亚硝酸盐残留的微晶纤维素、某些交联羧甲纤维素钠型号)已被证实可成为亚硝化剂来源;储存吸湿使分子运动性提高,固相亚硝化便有了条件,这也是监管强调制剂端评估的原因。 In oral solid dosage forms some excipients — microcrystalline cellulose carrying nitrite residue, certain grades of croscarmellose sodium — have been shown to be nitrosating-agent sources; moisture uptake on storage raises molecular mobility and solid-state nitrosation becomes possible, which is why regulators emphasise formulation-side assessment.
其三,降解路径中的「二次亚硝化」。Third, "secondary nitrosation" along degradation pathways. 光照与氧化会生成蝶啶环开环、侧链断裂等产物;若某段仍保留芳香仲胺且电子效应改变,其亚硝化倾向就与母体不同。强制降解若只盯母体的亚硝基峰,容易漏掉。 Light and oxidation generate ring-opened pteridines and cleaved side chains; where a fragment retains the aromatic secondary amine with altered electronics, its nitrosation tendency differs from the parent. Forced degradation that watches only the parent's nitroso peak will miss them.
三条路径的排查顺序建议是:The recommended order for screening the three routes is: 先制剂端、再共用设备、最后工艺路线formulation first, shared equipment second, synthetic route last。这个顺序与直觉相反,却贴合审评关注点:原料药端工艺描述通常较完整,制剂端的辅料来源、包装与储存条件才是资料里最薄的一环。. The order is counter-intuitive but matches what reviewers focus on: API process descriptions are usually complete, while excipient sourcing, packaging and storage conditions on the product side are the thinnest part of a dossier.
五、检测:为什么通用亚硝胺方法在这里不灵5. Detection: why generic nitrosamine methods fail here
常规亚硝胺方法(针对 NDMA、NDEA)的共同前提是分子量小、强极性、缺发色团,故 GC-MS/MS 顶空或 LC-MS/MS 配 APCI 成了标配。甲氨蝶呤的 N-亚硝基衍生物把前提全部推翻:Conventional nitrosamine methods (for NDMA, NDEA) assume low molecular weight, high polarity and no chromophore, which is why headspace GC-MS/MS or LC-MS/MS with APCI became standard. The N-nitroso derivative of methotrexate overturns every premise:
- 分子量大、极性大High molecular weight, high polarity:结构上只比母体多一个 NO、少一个 H,分子量约 468(母体 454),完全不挥发,GC 路线直接排除。: structurally the parent plus one NO and minus one H, MW about 468 (parent 454), completely non-volatile, so GC is ruled out.[3]
- 强紫外吸收Strong UV absorption:蝶啶环在 300 nm 附近强吸收,且与 N-亚硝基衍生物只差一个亚硝基、保留极近,UV 无法区分,须靠质谱母子离子对定性。: the pteridine ring absorbs strongly near 300 nm, and the derivative differs only by one nitroso group with very close retention, so UV cannot distinguish them and precursor–product ion pairs are needed for identification.
- 基质效应重Heavy matrix effects:高浓度母体在 ESI 源里压制痕量组分的离子化,直接进质谱定量会系统性偏低。: high concentrations of parent suppress ionisation of the trace component in the ESI source, so direct MS quantitation reads systematically low.
- 同分异构干扰Isomeric interference:谷氨酸侧链的酰胺氮理论上也可被亚硝化,稳定性差但可能给出相同母离子,须靠色谱分开。: the amide nitrogen of the glutamate side chain is theoretically nitrosatable too; the product is unstable but can give the same precursor ion, so chromatographic separation is required.
方法逻辑因此是「The method logic is therefore "先分离、再富集、后检测separate, then enrich, then detect」:C18 或 HILIC 拉开母体与衍生物间距(常需长梯度或混合模式柱);固相萃取或柱切换富集;MRM 通道定量,配同位素内标校正基质效应。": C18 or HILIC to open the gap between parent and derivative (often needing long gradients or mixed-mode columns); SPE or column switching for enrichment; MRM quantitation with an isotope-labelled internal standard to correct matrix effects.
验证中最易挨挑的是The points most likely to be challenged in validation are 专属性specificity与 and the 定量限quantitation limit。专属性要用「母体加标 + 强制亚硝化样品」双通道证明目标峰确来自亚硝化反应,而非同分异构降解物;定量限须低于最大剂量规格折算出的控制目标。. Specificity must show, through both spiked parent and force-nitrosated samples, that the target peak truly comes from nitrosation and not from an isomeric degradant; the quantitation limit must sit below the control target computed from the highest-dose strength.
六、同族横向对比:哪些亚硝胺能类比,哪些不能6. Cross-comparison across the family: which nitrosamines are analogous and which are not
行业谈亚硝胺常并举,三者化学其实差别很大,甲氨蝶呤与任何一类都不同。下表按The industry tends to lump nitrosamines together, but the chemistry differs widely, and methotrexate resembles none of them. The table below is ordered by 亚硝化位点的化学类型chemical type of the nitrosation site排列。.
| 品种Product | 亚硝化位点类型Nitrosation site type | 亚硝化难度Nitrosation difficulty | 主要来源Main source | 能否与甲氨蝶呤类比Comparable to methotrexate? |
|---|---|---|---|---|
| 甲氨蝶呤Methotrexate | 蝶啶环外芳香仲胺(N-芳基酰胺)Aromatic secondary amine outside the pteridine ring (N-aryl amide) | 中——碱弱但游离态比例高moderate — weak base but a high free fraction | NDSRI,工艺 + 制剂端双源NDSRI, dual source in process and formulation | — |
| 缬沙坦等沙坦类Valsartan and other sartans | 四唑/咪唑环上的仲胺或叔胺secondary or tertiary amine on the tetrazole/imidazole ring | 中至高,常需先脱烷基moderate to high, often requires prior dealkylation | 溶剂与试剂中的二甲胺等小分子胺small amines such as dimethylamine from solvents and reagents | 不能——属外来小分子亚硝胺no — an external small-molecule nitrosamine |
| 雷尼替丁Ranitidine↗ | Mannich 碱裂解产生的二甲胺dimethylamine released by cleavage of the Mannich base | 高(须先裂解)high (cleavage required first) | 降解产物再亚硝化degradant subsequently nitrosated | 不能——亚硝胺不是分子骨架的一部分no — the nitrosamine is not part of the molecular skeleton |
| 二甲双胍Metformin↗ | 二甲胺(由分子裂解或原料带入)dimethylamine (from molecular cleavage or raw materials) | 高high | 原料与辅料带入carried in by raw materials and excipients | 不能——分子本身无亚硝化位点no — the molecule has no nitrosatable site |
| 阿奇霉素Azithromycin↗等大环内酯 and other macrolides | 叔胺脱甲基后形成的仲胺secondary amine formed after demethylation of a tertiary amine | 高(须先脱甲基)high (demethylation required first) | NDSRI,双位点NDSRI, two sites | 部分可以——同属 NDSRI,但位点在脂肪胺partly — also an NDSRI, but the site is an aliphatic amine |
表注:判定的关键是「位点是否在分子骨架上」与「位点是否芳香化」。前者决定它是不是 NDSRI,后者决定亚硝化动力学与检测难度。Table note: the decisive questions are whether the site lies on the molecular skeleton and whether it is aromatic. The first decides whether it is an NDSRI; the second governs nitrosation kinetics and detection difficulty.
七、申报与发补:三个高频问题7. Filing and deficiency responses: three frequent issues
甲氨蝶呤的国内申报是「老品种、多规格、持续补充申请」的典型。按 CDE 受理品种信息公开数据(2026-11-02 抓取),以「甲氨蝶呤」检索共 Domestic filings for methotrexate are the classic pattern of an old product with many strengths and continuous supplemental applications. According to CDE public acceptance data (retrieved 2026-11-02), a search on methotrexate returns 243 条243 acceptance records[4],涉及 from 73 家73 applicants申报单位。.
说明它随规格扩展与工艺变更持续提交。 which shows continuous submission as strengths expand and processes change.被反复追问三类问题:Three issues come up repeatedly:
- 为什么只做了原料药、没做制剂?Why cover only the API and not the product? 固体制剂中亚硝化可持续发生,仅原料药数据不足。发补通常要求制剂端风险评估:辅料亚硝酸盐声明、包装阻隔性、加速与长期趋势数据。 Nitrosation can continue in a solid dosage form, so API data alone is insufficient. Deficiency letters typically demand a formulation-side risk assessment: excipient nitrite declarations, packaging barrier properties and accelerated plus long-term trend data.
- 限度依据从哪来?Where does the limit basis come from? 只写「按 ICH M7 的 TTC 折算」 Writing only "converted from the ICH M7 TTC"[1] 不够,须给出日剂量取值、AI 来源(化合物特异数据还是交叉参照)与换算过程。剂量跨度大,取值一含糊,整套限度的可信度就没了。 is not enough; you must give the daily dose used, the AI source (compound-specific data or read-across) and the calculation. With such a wide dose range, one vague input destroys the credibility of the whole limit.
- 方法定量限是否足够?Is the method's quantitation limit sufficient? 这也是最容易挨挑的一点。方法 LOQ 若高于最大规格折算出的控制目标,数据「未检出」也不能证明合规——未检出只说明低于 LOQ,不说明低于限度。 This is the easiest point to challenge. If the method LOQ is above the control target computed for the highest strength, a "not detected" result does not demonstrate compliance — not detected only means below LOQ, not below the limit.
另一点易被忽略:One more point often overlooked: 稳定性方案须单设亚硝胺考察点the stability protocol needs a dedicated nitrosamine test point。常规「有关物质 + 含量 + 溶出」并不覆盖痕量亚硝胺. The usual "related substances plus assay plus dissolution" set does not cover trace nitrosamines[5],只在 0 月与 24 月各测一次无从判断趋势;应在加速条件下加密取样,把它作为独立考察项。, and measuring only at 0 and 24 months leaves no way to judge trend; increase sampling under accelerated conditions and treat it as an independent test item.
八、四个常见误区8. Four common misconceptions
误区一:碱性越强越易被亚硝化。Misconception 1: the stronger the base, the easier the nitrosation. 恰恰相反。第一步是游离胺与 NO⁺ 结合,质子化是竞争反应;碱性弱的芳香胺与酰胺氮,被质子夺走的少,游离态比例反而高——这正是甲氨蝶呤需要单独评估的原因。 Quite the opposite. The first step is free amine combining with NO⁺, with protonation as the competing reaction; for weakly basic aromatic amines and amide nitrogens fewer molecules are taken by protons, so the free fraction is higher — exactly why methotrexate needs its own assessment.
误区二:EP 杂质 L 只是个字母,买同名对照品即可。Misconception 2: EP Impurity L is just a letter, so buy the standard with the matching name. 本目录以「EP 杂质 L」命名的条目已有 CAS 不同的两条,另有同分子式条目;字母是药典编排,不是结构唯一标识。 This catalogue already holds two entries named "EP Impurity L" with different CAS numbers, plus others sharing the formula; the letter is compendial bookkeeping, not a unique structural identifier.
误区三:剂量大所以限度宽松。Misconception 3: a high dose means a lenient limit. 方向反了。剂量大即分母大,同一 AI 折算出的 ppm 更低更严;宽松出现在小剂量、低频给药的规格上。 Backwards. A high dose is a large denominator, so the same AI yields a lower, stricter ppm; leniency appears at low-dose, low-frequency strengths.
误区四:只在原料药端控制就够了。Misconception 4: controlling the API is enough. 辅料亚硝酸盐与水分会让亚硝化在储存期继续推进,原料药合格、制剂超标已有先例,甲氨蝶呤同样需要制剂端评估。 Nitrite in excipients plus moisture lets nitrosation proceed during storage; there are precedents of compliant API and out-of-specification product, and methotrexate needs a formulation-side assessment too.
围绕 N-亚硝基杂质 L,以下是采购、方法与申报三端最常被问到的问题。Around N-nitroso Impurity L, these are the questions most often asked about sourcing, method and filing.
常见问题(FAQ)Frequently asked questions
甲氨蝶呤的 N-亚硝基杂质为什么归在 NDSRI 而不是普通亚硝胺?Why is methotrexate's N-nitroso impurity classed as an NDSRI rather than an ordinary nitrosamine?
EP 杂质 L 到底对应哪个 CAS?为什么目录里出现两条?Which CAS does EP Impurity L actually correspond to? Why are there two?
为什么说甲氨蝶呤的亚硝胺不能照搬 NDMA 的检测方法?Why can't NDMA methods simply be reused for methotrexate's nitrosamine?
甲氨蝶呤的剂量跨度对限度设定意味着什么?What does methotrexate's dose range mean for limit setting?
制剂端为什么也要评估?原料药合格还不够吗?Why assess the formulation side? Is a compliant API not enough?
稳定性研究里要单设亚硝胺考察项吗?Should stability studies include a dedicated nitrosamine test item?
光解产物会影响亚硝胺的检测吗?Do photolysis products interfere with nitrosamine detection?
相关品种与对照品Related products and reference standards
- 甲氨蝶呤 / MethotrexateMethotrexate(共 85 个杂质/衍生物条目)(85 impurity and derivative entries)
- 盐酸二甲双胍 / Metformin HydrochlorideMetformin Hydrochloride(共 - 个杂质/衍生物条目)(— impurity and derivative entries)
- 缬沙坦 / ValsartanValsartan(共 - 个杂质/衍生物条目)(— impurity and derivative entries)
参考资料与来源References and sources
- ICH,ICH M7《评估和控制药物中 DNA 反应性(致突变)杂质以限制潜在致癌风险》ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk,访问日期 2026-11-02, accessed 2026-11-02
- EMA,欧洲药品管理局(亚硝胺杂质相关指南与问答)European Medicines Agency (nitrosamine impurity guidance and Q&A),访问日期 2026-11-02, accessed 2026-11-02
- Int J Mol Sci(2023),Statistical Analysis of Methotrexate Degradation by UV-C Photolysis and UV-C/TiO2 Photocatalysis(甲氨蝶呤光解产物与转化路径)Statistical Analysis of Methotrexate Degradation by UV-C Photolysis and UV-C/TiO2 Photocatalysis (photolysis products and transformation pathways of methotrexate),访问日期 2026-11-02, accessed 2026-11-02
- 国家药品监督管理局药品审评中心,Center for Drug Evaluation, NMPA, CDE 受理品种信息(信息公开)CDE acceptance information (public disclosure),访问日期 2026-11-02, accessed 2026-11-02
- ICH,ICH 质量类指南汇总(含 Q3A/Q3B/Q1A 稳定性)ICH quality guidelines collection (including Q3A/Q3B/Q1A stability),访问日期 2026-11-02, accessed 2026-11-02
说明:本文为 CATO 佳途技术团队原创整理,其中引用的法规、药典与公开文献内容已在上方标注来源,仅用于技术交流与检索参考,不构成质量标准或法规建议;具体品种的检测方法、限值与申报要求,请以现行法规、药典正文及官方发布为准。Note: this article was compiled by the CATO technical team; the regulations, pharmacopoeial texts and public literature cited are sourced above. It is provided for technical exchange and reference only and does not constitute a quality standard or regulatory advice; methods, limits and filing requirements for any specific product are governed by current regulations, compendial texts and official publications.
本站产品信息仅供科研检索与选型参考,不作为质量标准依据;技术参数、纯度与结构确证以随货 COA 及我方书面确认为准。本文涉及的产品均为科研用途,不用于人体或动物诊断、治疗。Product information on this site is for research search and selection reference only and is not a basis for quality standards; technical parameters, purity and structural confirmation are governed by the COA supplied with the goods and our written confirmation. All products discussed are for research use and are not intended for human or animal diagnosis or treatment.